Last reviewed 2026-04-20 · How we verify
PF-07868489 is an investigational drug by Pfizer for pulmonary arterial hypertension (PAH). Currently in Phase 2 trials, it aims to improve outcomes in PAH patients who have previously participated in clinical studies with the drug.
No approved indications tracked.
No common side effects on file.